Axel Bolte

Inozyme Pharma is a rare disease company focused on metabolic disorders. Inozyme is developing a portfolio of drug candidates that encompasses biologics, small molecules as well as gene therapy. The company is led by a team of industry veterans and is well financed by top-tier US venture capital firms.
Alex is, or has been a board member at several private and public biotech companies over the years. He is also the Head of the Advisory Panel of Turos Capital AG, a specialist advisory firm focused on healthcare. For 14 years he was an Investment Advisor at HBM Partners AG, a Swiss-based healthcare investment firm. He started investing at New Medical Technologies and previously worked at Serono SA in R&D.